Eurofins-Cerep SA (ALECR) fair value: what the stock is really worth
As of Oct 23, 2026: fair value (intrinsic value) of Eurofins-Cerep SA stock €11,679, price €18,400, that is 36.5% below the price, quality 61 out of 100. Rating: strongly overvalued. Calculated from audited financials with 21 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 5, 2026.
How to read this chart
60‑month range €3,675 – €29,200 · fair‑value band €8,567 – €15,321 · the €18,400 price screens above the €11,679 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 2 fiscal years are left out: there the valuation rested on only a fraction of the usual models. As of Nov 5, 2026.
Follow Eurofins-Cerep in your weekly email
Every Wednesday you see whether Eurofins-Cerep is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Eurofins-Cerep SA provides various drug discovery services to pharmaceutical, biopharmaceutical, and biotechnology companies France and internationally. The company's research services include compound management, and high-throughput screening and profiling.
Show moreShow less
The company was formerly known as Cerep SA and changed its name to Eurofins-Cerep SA in June 2014. Eurofins-Cerep SA was founded in 1989 and is based in Celle-Lévescault, France. Eurofins-Cerep SA is a subsidiary of Eurofins Discovery Services LUX Holding SARL.
Stock analysis
Eurofins-Cerep SA (ALECR) currently trades at €18,400, while our model-based Fair Value estimate is €11,679, 37% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of €17,284 per share, and 3 of the 21 models we run sit above the €18,400 price.
Bear case: the Growth DCF group reads lowest at €9,137, and 18 of the 21 models stay below the price. Data coverage for this calculation is medium.
Scenario range: €8,567 (bear) to €15,321 (bull), the price of €18,400 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 61/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Eurofins-Cerep SA reported revenue of €41.0M in FY2025 versus €41.6M in FY2021, a compound −0.4%/yr. Reported net income was €4.8M in FY2025, compounding −16.5%/yr from FY2021.
Key figures
Market cap €92.8M Micro · P/E ratio 11.9 · P/S ratio 1.39 · EPS (TTM) €1,540 · Net margin 11.6% · Return on equity 6.5% · Return on assets (EBIT) 10.1% (5-year average) · Operating margin 10.2%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 46 out of 100 (low confidence).
What moves the price
The share trades about 1% below its 52-week high and 23% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −9% fair-value upside, at −37%, ALECR screens richer than that median.
Fair Value models
Bear€8,567Fair Value €11,679Bull€15,321
Price €18,400 · Downside -36.5%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (€1,321 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+1.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−4.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.6%
Start year 2020 (pandemic). Over 10 years: +6.2% a year
Revenue growth 25 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.3%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−3.0%
Earnings growth per share plus dividend.
Earnings per share, growth per year−3.0%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−3.0% vs 8.3%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.17% → 9%
Pace: the 5-year rate starts in 2020 (pandemic)
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+16.9%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (euro area: IMF forecast 2.2% a year to 2030, 2.6% from 2016 to 2025) that is about +14.4% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 126 stocks
Beats the industry median on 9/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score61 · Above median
Fair Value upside−36.5% · Below median
Profitability
Return on equity (12 months)6.5% · Above median
Return on assets5.4% · Above median
Net margin (12 months)11.6% · Above median
Operating margin (12 months)10.2% · Below median
Growth and dividend
Revenue growth (quarter YoY)10.9% · Above median
Valuation Multiplesvs Diagnostics & Research median · lower = cheaper
P/E (12 months)11.9× · Cheapest 25%
P/B1.21× · Cheaper than median
P/S (12 months)2.26× · Cheaper than median
Price / free cash flow (fiscal year)29.2× · Pricier than median
EV/EBITDA14.6× · Cheaper than median
PEG3.26× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)55· sector 39
PAST (return on equity)26· sector 15
HEALTH (low debt)100· sector 95
DIVIDEND (yield)0· sector 33
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Eurofins-Cerep SA Fair Value". https://www.fairvalue-calculator.com/stock/ALECR
Frequently asked questions
Is Eurofins-Cerep SA (ALECR) overvalued or undervalued?
As of Nov 5, 2026, our model estimates a fair value of €11,679 versus the last price from Oct 23, 2026 of €18,400, about 37% lower (overvalued).
What is the fair value of ALECR?
Our model-based fair value for Eurofins-Cerep SA is €11,679 (as of Nov 5, 2026), built from audited fundamentals. Last price (from Oct 23, 2026): €18,400.
What is the quality score of ALECR?
Eurofins-Cerep SA has a Quality Score of 61/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Eurofins-Cerep SA (ALECR)?
Our model-based price target is the fair value of €11,679 (as of Nov 5, 2026) from 21 valuation models. Cautious scenario €8,567, optimistic scenario €15,321. It is a calculation from audited fundamentals, not an analyst target.
What is the Eurofins-Cerep SA stock forecast for 2026?
Our models put fair value at €11,679, about 37% lower versus the last price from Oct 23, 2026 of €18,400 (overvalued). Cautious scenario €8,567, optimistic scenario €15,321. The calculation is refreshed regularly with new filings.
What is the revenue of Eurofins-Cerep SA (ALECR)?
Eurofins-Cerep SA reported trailing-twelve-month revenue of about €41.1M (latest available figure, as of Nov 5, 2026).
What growth is priced into Eurofins-Cerep SA (ALECR)?
For today's price to be fair in a discounted-cash-flow model, Eurofins-Cerep SA would have to grow free cash flow by +16.9 % per year for five years (discount rate 11.8 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +4.6 % per year. As of Nov 5, 2026.
What discount rate (WACC) does the fair value of ALECR use?
Our models discount Eurofins-Cerep SA at 11.8 %: a base by market capitalisation (micro), damped by beta 0.11, country premium for France. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Eurofins-Cerep SA that is +16.9 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (11.8 %) and the same formula as our fair value.
How much growth has Eurofins-Cerep SA (ALECR) delivered so far?
Over the past 5 years revenue at Eurofins-Cerep SA grew +4.6 % a year. The price currently implies free-cash-flow growth of +16.9 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Eurofins-Cerep SA (ALECR) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Eurofins-Cerep SA (+16.9 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Eurofins-Cerep SA (ALECR)?
The free-cash-flow yield on the price is 3.42 %: that much free cash flow Eurofins-Cerep SA produces per unit of market value. When it exceeds the discount rate of our models (11.8 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Eurofins-Cerep SA (ALECR)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Eurofins-Cerep SA it is €11,679 per share (as of Nov 5, 2026), against a price of €18,400. It is the blended result of 21 valuation models in 7 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Eurofins-Cerep SA stock overvalued or undervalued in 2026?
As of Nov 5, 2026, ALECR trades above its calculated fair value: price €18,400, fair value €11,679, a gap of about −37% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ALECR?
No. The price is what the market pays today (€18,400); the fair value is what the company's own numbers justify (€11,679). For Eurofins-Cerep SA the two are €6,721 per share apart. That gap is exactly why we show both numbers side by side.
How much is Eurofins-Cerep SA worth?
The market values Eurofins-Cerep SA at about €92.8M (market capitalisation, as of Nov 5, 2026). Per share that is €18,400; our models calculate a fair value of €11,679 per share.
What do the bullish and bearish scenarios say about ALECR?
Our models span a range for Eurofins-Cerep SA: cautious scenario €8,567, base €11,679, optimistic €15,321 per share (as of Nov 5, 2026, price €18,400). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of ALECR?
Eurofins-Cerep SA trades at a price-to-earnings ratio of 11.9 (as of Nov 5, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of €11,679 is built from several models across several years. Median P/E at fiscal year-end, 6 fiscal years (2017 to 2025), reported earnings: 10.3. Other multiples: PEG 3.3, P/B 1.2, P/S 2.3, EV/EBITDA 14.6.
What is the PEG ratio of ALECR?
The PEG ratio of Eurofins-Cerep SA is 3.26 (P/E divided by earnings growth, as of Nov 5, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Eurofins-Cerep SA (ALECR)?
Balance-sheet figures for Eurofins-Cerep SA (as of Nov 5, 2026): return on equity 6.5%. They feed the Quality Score of 61/100, which measures business quality independently of the share price.
How far is ALECR from its 52-week high?
Eurofins-Cerep SA trades at €18,400, about 1% below its 52-week high of €18,600 and 23% above the low of €15,000 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of €11,679 is for.
Which stocks are comparable to Eurofins-Cerep SA?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Lonza Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Eurofins-Cerep SA stock attractive at the current price?
The data as of Nov 5, 2026: price €18,400, calculated fair value €11,679 (−37%), Quality Score 61/100, from 21 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ALECR calculated?
We run Eurofins-Cerep SA through 21 models from 7 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of €11,679 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Eurofins-Cerep SA itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Eurofins-Cerep SA (ALECR)?
The latest price we hold is from Oct 23, 2026 and stands at €18,400. Our model-based fair value is €11,679, about 37% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Eurofins-Cerep SA right now?
The price sits above even our optimistic bull case (€15,321). The favourable scenario is already priced in. Solid but not exceptional quality (61/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of Eurofins-Cerep SA
How large is the market capitalisation of Eurofins-Cerep SA (ALECR)?
The market capitalisation of Eurofins-Cerep SA is €92.8M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Eurofins-Cerep SA (ALECR)?
The price-to-sales ratio of Eurofins-Cerep SA is 1.39 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Eurofins-Cerep SA (ALECR)?
Earnings per share at Eurofins-Cerep SA are €1,540 (price ÷ EPS = P/E 11.9). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Eurofins-Cerep SA (ALECR)?
The net margin of Eurofins-Cerep SA is 11.6% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Eurofins-Cerep SA (ALECR)?
The return on equity (ROE) of Eurofins-Cerep SA is 6.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Eurofins-Cerep SA (ALECR)?
On an EBIT basis the return on assets of Eurofins-Cerep SA is 10.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Eurofins-Cerep SA (ALECR)?
The operating margin of Eurofins-Cerep SA is 10.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Eurofins-Cerep SA (ALECR)?
Revenue at Eurofins-Cerep SA is growing +10.9% versus a year earlier (3y avg −4.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much net cash does Eurofins-Cerep SA (ALECR) hold?
Eurofins-Cerep SA holds more cash than debt, €9.1M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Eurofins-Cerep SA in the live analysis
One click puts Eurofins-Cerep SA on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 5, 2026